CSL Vifor and Travere Therapeutics Endorse New KDIGO Guidelines for IgA Nephropathy Management CSL Vifor and Travere Therapeutics support the latest KDIGO clinical guidelines aimed at improving treatment outcomes for IgA Nephropathy, focusing on proteinuria control and kidney function.

CSL Vifor and Travere Therapeutics Endorse New KDIGO Guidelines for IgA Nephropathy Management #USA #San_Diego #IgA_nephropathy #CSL_Vifor #Travere_Therapeutics

CSL Vifor and Travere Therapeutics Celebrate EU Approval of FILSPARI for IgA Nephropathy Treatment CSL Vifor and Travere Therapeutics have successfully converted FILSPARI's conditional approval into standard EU authorization for IgA Nephropathy treatment.

CSL Vifor and Travere Therapeutics Celebrate EU Approval of FILSPARI for IgA Nephropathy Treatment #Switzerland #CSL_Vifor #Travere_Therapeutics #FILSPARI #St._Gallen

EU Approves FILSPARI® for Treating IgA Nephropathy, Revolutionizing Patient Care CSL Vifor and Travere Therapeutics celebrate the EU's approval of FILSPARI® for IgA nephropathy, marking a crucial advancement in treatment options for patients in Europe.

EU Approves FILSPARI® for Treating IgA Nephropathy, Revolutionizing Patient Care #None #IgA_nephropathy #CSL_Vifor #Travere_Therapeutics